References1
1 S.M. Grunberg, D. Osoba and P.J. Hesketh et al., Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update, Support Care Cancer 13 (2005), pp. 80–84 [15599601]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (68)
2 C.M. Booth, M. Clemons and G. Dranitsaris et al., Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study, J Support Oncol 5 (2007), pp. 374–380 [17944146]. View Record in Scopus | Cited By in Scopus (10)
3 M. de Boer-Dennert, R. de Wit and P.I. Schmitz et al., Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists, Br J Cancer 76 (1997), pp. 1055–1061 [9376266]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (128)
4 P. Eisenberg, J. Figueroa-Vadillo, R. Zamora et al. and 99-04 Palonosetron Study Group, Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron, Cancer 98 (2003), pp. 2473–2482 [14635083]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (171)
5 R. Gralla, M. Lichinitser and S. Van Der Vegt et al., Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron, Ann Oncol 14 (2003), pp. 1570–1577 [14504060]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (177)
6 M. Saito, K. Aogi and I. Sekine et al., Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial, Lancet Oncol 10 (2009), pp. 115–124 [19135415]. Article | 
7 D.G. Warr, P.J. Hesketh and R.J. Gralla et al., Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy, J Clin Oncol 23 (2005), pp. 2822–2830 [15837996]. View Record in Scopus | Cited By in Scopus (139)
8 American Society of Clinical Oncology, M.G. Kris, P.J. Hesketh and M.R. Somerfield et al., American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006, J Clin Oncol 24 (2006), pp. 2932–2947 [16717289]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (311)
9 D.S. Ettinger, D.K. Armstrong and S. Barbour et al., National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology—Antiemesis, version 2.2010 http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf Accessed September 20, 2010.
10 R.W. Carlson and B. McCormick, Update: NCCN breast cancer clinical practice guidelines, J Natl Compr Cancer Netw 3 (suppl 1) (2005), pp. S7–S11 [16280118].
11 The Italian Group for Antiemetic Research, Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer, N Engl J Med 332 (1995), pp. 1–5 [7990859].
12 The Italian Group for Antiemetic Research, Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy, N Engl J Med 342 (2000), pp. 1554–1559 [10824073].
13 S.M. Grunberg, M. Dugan and H. Muss et al., Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy, Support Care Cancer 17 (2009), pp. 589–594 [19037667]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (14)
14 J. Herrstedt, H.B. Muss and D.G. Warr et al., Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy, Cancer 104 (2005), pp. 1548–1555 [16104039]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (43)
15 Centers for Medicare and Medicaid Services, Medicare Part B Drug Average Sales Price: 2008 ASP Drug Pricing Files http://www.cms.hhs.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/downloads/July2008ASPPricingFilebyHCPCS.zip Accessed July 18, 2008.
16 Thomson. Medstat, 1997–2002 MarketScan Health and Productivity Management Database User Guide and Data Dictionary, Thomson Medstat, Ann Arbor, MI (2003).
17 Centers for Medicare and Medicaid Services, National Physician Fee Schedule and Relative Value: 2008 Physician Fee Schedule National Payment Amount File http://www.cms.hhs.gov/PFSlookup/02_PFSSearch.asp Accessed July 18, 2008.
18 National Inpatient Sample (NIS), NIS description of data elements, Healthcare Cost and Utilization Project (HCUP) databases, Agency for Healthcare Research and Quality, Rockville, MD (2004) http://www.hcup-us.ahrq.gov/nisoverview.jsp#Data Accessed May 16, 2010.
19 S. Haislip, J. Gilmore, W.H. Lenz, T. Gondesen and B. Feinberg, Theory in practice: improving patient outcomes and practice efficiency with a simple change in 5-HT3 receptor antagonist for preventing chemotherapy-induced nausea and vomiting (CINV) In: Third Annual Meeting of the Hematology/Oncology Pharmacy Association; Abstract #PR6. June 14–16, 2007; Denver, Colorado http://www.hoparx.org/documents/2007programbook.pdf Accessed November 2, 2010.
20 C.C. Sun, D.C. Bodurka and C.B. Weaver et al., Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer, Support Care Cancer 13 (2005), pp. 219–227 [15538640]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (53)
21 M.F. Drummond, M.J. Sculpher, G.W. Torrance, B.J. O'Brien and G.L. Stoddart, Methods for the Economic Evaluation of Health Care Programmes (3rd ed.), Oxford University Press, New York (2005).
22 J. Hayman, J. Weeks and P. Mauch, Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy, Int J Radiat Oncol Biol Phys 35 (1996), pp. 827–841 [8690653]. Article |
23 B.E. Hillner, J.C. Weeks, C.E. Desch and T.J. Smith, Pamidronate in prevention of bone complications in metastatic breast cancer: a cost–effectiveness analysis, J Clin Oncol 18 (2000), pp. 72–79 [10623695]. View Record in Scopus | Cited By in Scopus (90)
24 S.D. Ramsey, Z. Liu and R. Boer et al., Cost–effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy, Value Health 11 (2008), pp. 172–179 [18673353].
25 B.E. Hillner, J.N. Ingle, R.T. Chlebowski et al. and American Society of Clinical Oncology, American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer, J Clin Oncol 21 (2003), pp. 4042–4057 [12963702]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (533)
26 T.J. Smith, J. Khatcheressian and G.H. Lyman et al., 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol 24 (2006), pp. 3187–3205 [16682719]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (485)
27 National Cancer Institute, Surveillance Epidemiology and End Results: SEER Stat Fact Sheets: Breast http://seer.cancer.gov/statfacts/html/breast.html Accessed May 16, 2010.
28 J.W. Tumeh, S.G. Moore, R. Shapiro and C.R. Flowers, Practical approach for using Medicare data to estimate costs for cost–effectiveness analysis, Expert Rev Pharmacoecon Outcomes Res 5 (2005), pp. 153–162 [19807571]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (5)
29 P.A. Ubel, R.A. Hirth, M.E. Chernew and A.M. Fendrick, What is the price of life and why doesn't it increase at the rate of inflation?, Arch Intern Med 163 (2003), pp. 1637–1641 [12885677]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (225)
30 J.C. Hornberger, D.A. Redelmeier and J. Petersen, Variability among methods to assess patients' well-being and consequent effect on a cost–effectiveness analysis, J Clin Epidemiol 45 (1992), pp. 505–512 [1588356]. Article |
31 R.A. Hirth, M.E. Chernew, E. Miller, A.M. Fendrick and W.G. Weissert, Willingness to pay for a quality-adjusted life year: in search of a standard, Med Decis Making 20 (2000), pp. 332–342 [10929856]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (291)
32 Y.C. Shih and M.T. Halpern, Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?, CA Cancer J Clin 58 (2008), pp. 231–244 [18596196]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (18)
33 E. Nadler, B. Eckert and P.J. Neumann, Do oncologists believe new cancer drugs offer good value?, Oncologist 11 (2006), pp. 90–95 [16476830]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (50)
34 R.S. Braithwaite, D.O. Meltzer, J.T. King Jr, D. Leslie and M.S. Roberts, What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?, Med Care 46 (2008), pp. 349–356 [18362813]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (64)
35 National Institutes of Health Consensus Development Panel, 1997 Consensus Statement: Breast Cancer Screening for Women Ages 40–49 http://consensus.nih.gov/1997/1997BreastCancerScreening103html.htm Accessed October 13, 2007.
36 P. Salzmann, K. Kerlikowske and K. Phillips, Cost–effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age, Ann Intern Med 127 (1997), pp. 955–965 [9412300]. View Record in Scopus | Cited By in Scopus (169)
37 Y.C. Shih, S. Han and S.B. Cantor, Impact of generic drug entry on cost–effectiveness analysis, Med Decis Making 25 (2005), pp. 71–80 [15673583]. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (6)
38 F. Roila, P.J. Hesketh, J. Herrstedt and Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer, Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference, Ann Oncol 17 (2006), pp. 20–28 [16314401]. View Record in Scopus | Cited By in Scopus (90)
39 S.M. Grunberg and A. Ireland, Epidemiology of chemotherapy-induced nausea and vomiting, Adv Studies Nurs 3 (1) (2005), pp. 9–15 http://www.jhasin.com/files/articlefiles/pdf/XASIN_3_1_p9_15.pdf Accessed September 16, 2010.
40 T. Grote, J. Hajdenberg, A. Cartmell, S. Ferguson, A. Ginkel and V. Charu, Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant, J Support Oncol 4 (2006), pp. 403–408 [17004515]. View Record in Scopus | Cited By in Scopus (38)
41 S.M. Grunberg, M. Dugan, H.B. Muss, M. Wood, S. Burdette-Radoux and T. Weisberg, Efficacy of a 1-day 3-drug antiemetic regimen for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy, J Clin Oncol 25 (18S) (2007), p. 9111.
42 U. S. Department of Labor. Bureau of Labor Statistics. Consumer Price Index http://www.bls.gov/cpi/home.htm Accessed May 16, 2010.
43 Department of Health and Human Services. Centers for Medicare & Medicaid Services, Medicare Program; Proposed Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2008 Rates CMS-1533-P, pp 1070–1073 http://www.cms.hhs.gov/AcuteInpatientPPS/downloads/CMS-1533-P.pdf Accessed May 16, 2010.